Modulation of cereblon levels by anti-myeloma agents

References

• Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565–1571.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001;98:492–494.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Tricot G, Anaissie E. Thalidomide in the management of multiple myeloma. Semin Oncol 2001;28:577–582.
   PubMed Web of Science ®Google Scholar
• Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet 2004;363:1802–1811.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Beksac M, Blade J, et al. Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist 2010;15:6–25.
   PubMed Web of Science ®Google Scholar
• Cavo M. A third-generation IMiD for MM. Blood 2011;118:2931–2932.
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Allred JB, Gertz MA, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 2011;118:2970–2975.
   PubMed Web of Science ®Google Scholar
• Aerbajinai W, Zhu J, Gao Z, et al. Thalidomide induces gamma-globin gene expression through increased reactive oxygen species-mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis. Blood 2007;110:2864–2871.
   PubMed Web of Science ®Google Scholar
• Parman T, Wiley MJ, Wells PG. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med 1999;5:582–585.
   PubMed Web of Science ®Google Scholar
• Stephens TD, Bunde CJ, Fillmore BJ. Mechanism of action in thalidomide teratogenesis. Biochem Pharmacol 2000;59:1489–1499.
   PubMed Web of Science ®Google Scholar
• Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. Science 2010;327:1345–1350.
   PubMed Web of Science ®Google Scholar
• Higgins JJ, Pucilowska J, Lombardi RQ, et al. A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation. Neurology 2004;63:1927–1931.
   PubMed Web of Science ®Google Scholar
• Jo S, Lee KH, Song S, et al. Identification and functional characterization of cereblon as a binding protein for large-conductance calcium-activated potassium channel in rat brain. J Neurochem 2005;94:1212–1224.
   PubMed Web of Science ®Google Scholar
• Lee KM, Jo S, Kim H, et al. Functional modulation of AMP-activated protein kinase by cereblon. Biochim Biophys Acta 2011;1813:448–455.
   PubMed Web of Science ®Google Scholar
• Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011;118:4771–4779.
   PubMed Web of Science ®Google Scholar
• Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012;26:2326–2335.
   PubMed Web of Science ®Google Scholar
• Heintel D, Rocci A, Ludwig H, et al. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol 2013;161:695–700.
   PubMed Web of Science ®Google Scholar
• Gandhi AK, Kang J, Havens CG, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN). Br J Haematol 2014;164:811–821.
   PubMed Web of Science ®Google Scholar
• Kronke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 2014;343:301–305.
   PubMed Web of Science ®Google Scholar
• Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 2014;343:305–309.
   PubMed Web of Science ®Google Scholar
• Diaz-Rodriguez E, Alvarez-Fernandez S, Chen X, et al. Deficient spindle assembly checkpoint in multiple myeloma. PLoS One 2011;6:e27583.
   PubMed Web of Science ®Google Scholar
• Cabrera N, Diaz-Rodriguez E, Becker E, et al. TrkA receptor ectodomain cleavage generates a tyrosine-phosphorylated cell-associated fragment. J Cell Biol 1996;132:427–436.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071–3076.
   PubMed Web of Science ®Google Scholar
• Broyl A, Kuiper R, van Duin M, et al. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood 2012;121:624–627.
   PubMed Web of Science ®Google Scholar
• Huang SY, Lin CW, Lin HH, et al. Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma. Ann Hematol 2014;93:1371–1380.
   PubMed Web of Science ®Google Scholar
• Schuster SR, Kortuem KM, Zhu YX, et al. The clinical significance of cereblon expression in multiple myeloma. Leuk Res 2014;38:23–28.
   PubMed Web of Science ®Google Scholar
• Gandhi AK, Mendy D, Waldman M, et al. Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. Br J Haematol 2013;164:233–244.
   PubMed Web of Science ®Google Scholar
• Thakurta A, Gandhi AK, Waldman MF, et al. Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy. Leukemia 2014;28:1129–1131.
   PubMed Web of Science ®Google Scholar
• Greenberg AJ, Walters DK, Kumar SK, et al. Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels. Eur J Haematol 2013;91:504–513.
   PubMed Web of Science ®Google Scholar